Login / Signup

A constructive critique of the draft ICH E9 Addendum.

Daniel O Scharfstein
Published in: Clinical trials (London, England) (2019)
In this article, I review the key elements of the proposed International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 Addendum, present a constructive critique, and provide recommendations of how it can be improved. To highlight ideas, I present a case study involving a confirmatory trial for a chronic pain medication.
Keyphrases
  • chronic pain
  • endothelial cells
  • study protocol
  • clinical trial
  • pain management
  • healthcare
  • phase iii
  • pluripotent stem cells
  • phase ii
  • clinical practice
  • emergency department
  • double blind